首页> 外文期刊>Hematological oncology >Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome
【24h】

Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome

机译:降低强度的真菌病菌和Sezary综合征后的同种异体造血干细胞移植

获取原文
获取原文并翻译 | 示例
           

摘要

Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS. With a median follow-up period of 954days after HSCT, the estimated 3-year overall survival was 85.7% (95% confidence interval, 33.4-97.9%) with no non-relapse mortality. Five patients relapsed after RIC-HSCT; however, in four patients whose relapse was detected only from the skin, persistent complete response was achieved in one patient, and the disease was manageable in other three patients by the tapering of immunosuppressants and donor lymphocyte infusion, suggesting that graft-versus-lymphoma effect and down-staging' effect from advanced stage to early stage by HSCT improve the prognosis of advanced-stage MF/SS. These results suggest that RIC-HSCT is an effective treatment for advanced MF/SS. Copyright (c) 2014 John Wiley & Sons, Ltd.
机译:晚期真菌病真菌病和Sezary综合征(MF / SS)的预后较差。异基因造血干细胞移植(HSCT),特别是使用降低强度调节(RIC)方案,是晚期MF / SS的有前途的治疗方法。我们对9例晚期MF / SS患者进行了RIC-HSCT。 HSCT后的中位随访期为954天,估计的3年总生存率为85.7%(95%置信区间为33.4-97.9%),无非复发死亡率。 RIC-HSCT术后复发5例。然而,在仅从皮肤中检测到复发的四名患者中,一名患者实现了持续的完全缓解,而其他三名患者通过逐渐减少免疫抑制剂和输注供体淋巴细胞可以控制该疾病,这表明移植物抗淋巴瘤的作用HSCT从晚期到早期的降级作用改善了晚期MF / SS的预后。这些结果表明,RIC-HSCT是治疗晚期MF / SS的有效方法。版权所有(c)2014 John Wiley&Sons,Ltd.

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号